Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
11 evidence topics · 10 sources
Subgroup assessment for semaglutide and tirzepatide in the ICER review
Race and ethnicity: representation and weight loss in incretin trials
Sex, age, and region: semaglutide 2.4 mg in SELECT
“Women had a greater difference in mean weight loss with semaglutide versus placebo (−11.1% (95% CI −11.56 to −10.66) versus −7.5% in men (95% CI −7.78 to −7.23); P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a linear relationship between age category and degree of mean weight loss, with younger age being associated with progressively greater mean weight loss, but the actual mean difference by age group is small.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients from Asia and of Asian race experienced slightly lower mean weight loss (estimated treatment difference with semaglutide for Asian race −7.27% (95% CI −8.09 to −6.46; P = 0.0147) and for Asia −7.30 (95% CI −7.97 to −6.62; P = 0.0016)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reproductive stage: tirzepatide in women in SURMOUNT-1
“In SURMOUNT‐1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diabetes status: tirzepatide in SURMOUNT-1, adults without diabetes
“The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diabetes status: tirzepatide in SURMOUNT-2, adults with type 2 diabetes
Diabetes status: semaglutide 7.2 mg in STEP UP, adults without diabetes
“The mean change in bodyweight was greater with semaglutide 7·2 mg versus 2·4 mg (-18·7% [SE 0·4] vs -15·6% [0·7]; estimated treatment difference [ETD] -3·1% [95% CI -4·7 to -1·6]; p<0·0001) and with semaglutide 7·2 mg versus placebo (-18·7% [0·4] vs -3·9% [0·6]; -14·8% [-16·2 to -13·4]; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diabetes status: semaglutide 7.2 mg in STEP UP T2D, adults with type 2 diabetes
Age 65 years and older: oral orforglipron in ATTAIN-1 and ATTAIN-2
“At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was −7.9% (95% CI: −10.0, –5.9), −11.3% (−13.4, −9.3), and −13.0% (−15.7, −10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. −1.6% (−3.2, 0.1) with placebo (all p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparable findings were observed in participants <65 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: BMI category change by baseline obesity class in VENTURE
Diabetes status: survival after metabolic-bariatric surgery
“In subgroup analyses, both individuals with (hazard ratio 0·409, 95% CI 0·370-0·453, p<0·0001) or without (0·704, 0·588-0·843, p<0·0001) baseline diabetes who underwent metabolic-bariatric surgery had lower rates of all-cause mortality, but the treatment effect was considerably greater for those with diabetes (between-subgroup I2 95·7%, p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote